AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone corresponding to amino acids 177–191 of the C-terminus of hGH, with an added tyrosine residue at the N-terminus for stability. It was originally developed by Metabolic Pharmaceuticals in Australia as a potential anti-obesity drug and reached Phase 3 clinical trials before the program was discontinued on commercial grounds.
AOD-9604's key pharmacological distinction from full-length hGH is selectivity: it retains the fat-metabolism activity of hGH (stimulating lipolysis and inhibiting lipogenesis) while lacking hGH's glucose-elevating, mitogenic, and cartilage-stimulating effects. This selectivity makes it a focused research tool for studying the specific fat-metabolism arm of the GH receptor signaling pathway without confounding full-GH effects.
AOD-9604 was granted GRAS (Generally Recognized As Safe) status by the US FDA in 2014 for use as a food ingredient, providing a safety reference that distinguishes it from many research compounds — though it remains for laboratory research use only at OPSEK Labs.
Third-party tested · Lot-specific COA · US domestic shipping 24–48h
Buy AOD-9604 Now →| Purity | ≥99% (HPLC verified, third-party) |
| Molecular Weight | 1,817.1 Da |
| Appearance | White lyophilized powder |
| Storage | –20°C long-term; 4°C up to 14 days after reconstitution |
| Lot Number | OL-2026-010 |
| Format | Lyophilized powder, sealed vial |
| Certificate of Analysis | Lot-specific COA included with every order |
| Intended Use | In vitro laboratory research only |
| hGH Fragment | AA 177–191 + N-terminal Tyr (C-terminal hGH fragment) |
Research Use Disclaimer: AOD-9604 is sold strictly for in vitro laboratory research purposes only. Not for human consumption, veterinary use, or clinical application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.